<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514369</url>
  </required_header>
  <id_info>
    <org_study_id>ARVLB01</org_study_id>
    <nct_id>NCT02514369</nct_id>
  </id_info>
  <brief_title>Pharmacogenomics of New Antiretrovirals</brief_title>
  <official_title>Pharmacogenetics of New Antiretroviral Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some genetic polymorphisms are known to interfere with ARV metabolism and are therefore
      likely to explain some of the inter-individual variations (efficacy,toxicity,resistance)
      observed during ART. The most common form of human DNA variations consists of a change of a
      base in the nucleotide sequence of an individual at a given position, the single nucleotide
      polymorphism (SNP). Therefore,the purpose of this research will be the identification and
      characterization of the clinical impact of several SNPs in gene coding for transport proteins
      (e.g.ABCB1,ABCC1) and biotransformation enzymes (e.g.CYP3A4,CYP2B6) known to be involved in
      the pharmacokinetic pathway of selected ARV drugs for which the therapeutic response is
      difficult to predict. Aside,the influence of these SNPs on the response to treatment
      (CD4+cell,viral load) and on the toxicity will be evaluated. Plasma concentrations of ARV
      drugs correlate with therapeutic efficacy but also with the risk of toxicity and of
      virological failure, which is the basis of the therapeutic drug monitoring. However,given the
      intracellular location of HIV, analyzing intracellular drug concentrations is fundamental and
      the investigators will also focus of this new topic.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of pharmacogenomics on plasma concentration of new antiretroviral drugs</measure>
    <time_frame>up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of pharmacogenomics on intracellular concentration of new antiretroviral drugs</measure>
    <time_frame>up to 48 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>HIV</condition>
  <eligibility>
    <study_pop>
      <textblock>
        HIV1-positive patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 positive treated with drug of interest

        Exclusion Criteria:

          -  &lt;18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leila Belkhir, MD</last_name>
    <phone>003227647087</phone>
    <email>leila.belkhir@uclouvain.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila Belkhir, MD</last_name>
      <phone>003227647087</phone>
      <email>leila.belkhir@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Vincent Haufroid, Pharm PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Vandercam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2015</study_first_posted>
  <last_update_submitted>July 31, 2015</last_update_submitted>
  <last_update_submitted_qc>July 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

